628 related articles for article (PubMed ID: 30449777)
1. Bicytopenia in Primary Lung Melanoma Treated with Nivolumab.
Takahashi A; Kubo A; Mizuno S; Kasai K; Asai N; Yonezawa T; Kosaka K; Nishimura M; Tanaka H; Yokoe N; Tsuzuki T; Takami A; Yamaguchi E
Intern Med; 2019 Mar; 58(6):827-831. PubMed ID: 30449777
[TBL] [Abstract][Full Text] [Related]
2. Febrile Neutropenia in a Patient with Non-Small Cell Lung Cancer Treated with the Immune-Checkpoint Inhibitor Nivolumab.
Hisamatsu Y; Morinaga R; Watanabe E; Ohtani S; Shirao K
Am J Case Rep; 2020 Feb; 21():e920809. PubMed ID: 32018275
[TBL] [Abstract][Full Text] [Related]
3. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
de Jong C; Peters BJM; Schramel FMNH
Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I
J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma.
Tokumo K; Masuda T; Miyama T; Miura S; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Yoshida T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Lung Cancer; 2018 May; 119():21-24. PubMed ID: 29656748
[TBL] [Abstract][Full Text] [Related]
6. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
[TBL] [Abstract][Full Text] [Related]
7. Erythema Nodosum as the Initial Presentation of Nivolumab-Induced Sarcoidosis-Like Reaction.
Laroche A; Alarcon Chinchilla E; Bourgeault E; Doré MA
J Cutan Med Surg; 2018; 22(6):627-629. PubMed ID: 29772919
[TBL] [Abstract][Full Text] [Related]
8. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
Mishima Y; Fukaishi T; Inase N; Isogai S
Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
[TBL] [Abstract][Full Text] [Related]
11. Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression.
Meti N; Petrogiannis-Haliotis T; Esfahani K
J Oncol Pract; 2018 Aug; 14(8):514-516. PubMed ID: 30004823
[No Abstract] [Full Text] [Related]
12. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
13. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
Gao CA; Weber UM; Peixoto AJ; Weiss SA
J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
[TBL] [Abstract][Full Text] [Related]
14. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
15. Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma.
Baba T; Sakai F; Kato T; Kusumoto M; Kenmotsu H; Sugiura H; Tominaga J; Oikado K; Sata M; Endo M; Yanagawa N; Sasaki S; Iwasawa T; Saito Y; Fujiwara Y; Ohe Y; Yamazaki N; Sakamoto T; Koshiba T; Kuwano K
Future Oncol; 2019 Jun; 15(16):1911-1920. PubMed ID: 31020849
[No Abstract] [Full Text] [Related]
16. Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.
Anastasopoulou A; Papaxoinis G; Diamantopoulos P; Christofidou E; Benopoulou O; Stratigos A; Gogas H
J Immunother; 2018 Apr; 41(3):164-167. PubMed ID: 29309291
[TBL] [Abstract][Full Text] [Related]
17. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
[TBL] [Abstract][Full Text] [Related]
18. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
Messer A; Drozd B; Glitza IC; Lu H; Patel AB
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
[TBL] [Abstract][Full Text] [Related]
19. Bluish-gray fingernail discoloration due to the use of nivolumab.
Ocampo MM; Lerner J; Dasanu CA
J Oncol Pharm Pract; 2021 Mar; 27(2):457-459. PubMed ID: 32517636
[TBL] [Abstract][Full Text] [Related]
20. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
